Night Vision Disturbances Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major night vision disturbances markets reached a value of US$ 308.8 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 430.5 Million by 2034, exhibiting a growth rate (CAGR) of 3.07% during 2024-2034.
The night vision disturbances market has been comprehensively analyzed in IMARC's new report titled "Night Vision Disturbances Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Night vision disturbances refer to the impaired ability to see clearly in low-light conditions, often experienced as an unsettling disruption in one's visual perception during nighttime or dimly lit environments. Individuals suffering from the ailment may encounter a range of symptoms, such as difficulty discerning objects, increased sensitivity to glare, halos, or starbursts around lights, and decreased contrast sensitivity. These indications can affect the quality of life, particularly when engaging in activities that require adequate night vision, including driving or navigating in the dark. The diagnosis of the illness typically involves a comprehensive eye investigation by an ophthalmologist or optometrist. The healthcare professional will assess factors, such as refractive errors, pupil size, and the overall health of the eye's structures. In some cases, various specialized tests, like contrast sensitivity testing and measurements of the eye's aberrations, may be conducted to pinpoint the exact nature of the visual disturbance in patients.
The increasing cases of retinal abnormalities causing degeneration of the cells, particularly the rods responsible for dim light vision, are primarily driving the night vision disturbances market. In addition to this, the inflating utilization of innovative corrective methods, such as specialized glasses, contact lenses, and vitamin supplements, to enhance and protect night vision in individuals suffering from the disorder is also creating a positive outlook for the market. Moreover, the widespread adoption of advanced imaging procedures, including adaptive optics and retinal scans, which enable precise diagnosis and personalized treatment plans, thereby improving the quality of life, is further bolstering the market growth. Apart from this, the rising usage of cutting-edge interventions, like retinal implants and neurostimulation techniques, since they are aimed at mitigating the condition and restoring optimal nocturnal visual capabilities in patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of tailored vision therapies that are designed to enhance retinal sensitivity, refine neural adaptation, and ameliorate low-light vision is also propelling the market growth. Furthermore, the escalating application of gene-based interventions, encompassing gene augmentation and gene editing strategies, to help in rectifying the genetic anomalies responsible for the disorder is expected to drive the night vision disturbances market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the night vision disturbances market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for night vision disturbances and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the night vision disturbances market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the night vision disturbances market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the night vision disturbances market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current night vision disturbances marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the night vision disturbances market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the night vision disturbances market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the night vision disturbances market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of night vision disturbances across the seven major markets?
What is the number of prevalent cases (2018-2034) of night vision disturbances by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of night vision disturbances by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with night vision disturbances across the seven major markets?
What is the size of the night vision disturbances patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of night vision disturbances?
What will be the growth rate of patients across the seven major markets?
Night Vision Disturbances: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for night vision disturbances drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the night vision disturbances market?
What are the key regulatory events related to the night vision disturbances market?
What is the structure of clinical trial landscape by status related to the night vision disturbances market?
What is the structure of clinical trial landscape by phase related to the night vision disturbances market?
What is the structure of clinical trial landscape by route of administration related to the night vision disturbances market?
The night vision disturbances market has been comprehensively analyzed in IMARC's new report titled "Night Vision Disturbances Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Night vision disturbances refer to the impaired ability to see clearly in low-light conditions, often experienced as an unsettling disruption in one's visual perception during nighttime or dimly lit environments. Individuals suffering from the ailment may encounter a range of symptoms, such as difficulty discerning objects, increased sensitivity to glare, halos, or starbursts around lights, and decreased contrast sensitivity. These indications can affect the quality of life, particularly when engaging in activities that require adequate night vision, including driving or navigating in the dark. The diagnosis of the illness typically involves a comprehensive eye investigation by an ophthalmologist or optometrist. The healthcare professional will assess factors, such as refractive errors, pupil size, and the overall health of the eye's structures. In some cases, various specialized tests, like contrast sensitivity testing and measurements of the eye's aberrations, may be conducted to pinpoint the exact nature of the visual disturbance in patients.
The increasing cases of retinal abnormalities causing degeneration of the cells, particularly the rods responsible for dim light vision, are primarily driving the night vision disturbances market. In addition to this, the inflating utilization of innovative corrective methods, such as specialized glasses, contact lenses, and vitamin supplements, to enhance and protect night vision in individuals suffering from the disorder is also creating a positive outlook for the market. Moreover, the widespread adoption of advanced imaging procedures, including adaptive optics and retinal scans, which enable precise diagnosis and personalized treatment plans, thereby improving the quality of life, is further bolstering the market growth. Apart from this, the rising usage of cutting-edge interventions, like retinal implants and neurostimulation techniques, since they are aimed at mitigating the condition and restoring optimal nocturnal visual capabilities in patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of tailored vision therapies that are designed to enhance retinal sensitivity, refine neural adaptation, and ameliorate low-light vision is also propelling the market growth. Furthermore, the escalating application of gene-based interventions, encompassing gene augmentation and gene editing strategies, to help in rectifying the genetic anomalies responsible for the disorder is expected to drive the night vision disturbances market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the night vision disturbances market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for night vision disturbances and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the night vision disturbances market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the night vision disturbances market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the night vision disturbances market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current night vision disturbances marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the night vision disturbances market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the night vision disturbances market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the night vision disturbances market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of night vision disturbances across the seven major markets?
What is the number of prevalent cases (2018-2034) of night vision disturbances by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of night vision disturbances by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with night vision disturbances across the seven major markets?
What is the size of the night vision disturbances patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of night vision disturbances?
What will be the growth rate of patients across the seven major markets?
Night Vision Disturbances: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for night vision disturbances drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the night vision disturbances market?
What are the key regulatory events related to the night vision disturbances market?
What is the structure of clinical trial landscape by status related to the night vision disturbances market?
What is the structure of clinical trial landscape by phase related to the night vision disturbances market?
What is the structure of clinical trial landscape by route of administration related to the night vision disturbances market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NIGHT VISION DISTURBANCES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 NIGHT VISION DISTURBANCES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NIGHT VISION DISTURBANCES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 NIGHT VISION DISTURBANCES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 NIGHT VISION DISTURBANCES - UNMET NEEDS
10 NIGHT VISION DISTURBANCES - KEY ENDPOINTS OF TREATMENT
11 NIGHT VISION DISTURBANCES - MARKETED PRODUCTS
11.1 List of Night Vision Disturbances Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 NIGHT VISION DISTURBANCES - PIPELINE DRUGS
12.1 List of Night Vision Disturbances Pipeline Drugs Across the Top 7 Markets
12.1.1 Phentolamine mesylate ophthalmic solution - Ocuphire Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. NIGHT VISION DISTURBANCES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. NIGHT VISION DISTURBANCES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 NIGHT VISION DISTURBANCES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Night Vision Disturbances - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Night Vision Disturbances - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Night Vision Disturbances - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Night Vision Disturbances - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Night Vision Disturbances - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Night Vision Disturbances - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Night Vision Disturbances - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Night Vision Disturbances - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Night Vision Disturbances - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Night Vision Disturbances - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Night Vision Disturbances - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Night Vision Disturbances - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Night Vision Disturbances - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Night Vision Disturbances - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Night Vision Disturbances - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Night Vision Disturbances - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Night Vision Disturbances - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Night Vision Disturbances - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Night Vision Disturbances - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Night Vision Disturbances - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Night Vision Disturbances - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Night Vision Disturbances - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Night Vision Disturbances - Access and Reimbursement Overview
16 NIGHT VISION DISTURBANCES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 NIGHT VISION DISTURBANCES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 NIGHT VISION DISTURBANCES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NIGHT VISION DISTURBANCES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 NIGHT VISION DISTURBANCES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NIGHT VISION DISTURBANCES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 NIGHT VISION DISTURBANCES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 NIGHT VISION DISTURBANCES - UNMET NEEDS
10 NIGHT VISION DISTURBANCES - KEY ENDPOINTS OF TREATMENT
11 NIGHT VISION DISTURBANCES - MARKETED PRODUCTS
11.1 List of Night Vision Disturbances Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 NIGHT VISION DISTURBANCES - PIPELINE DRUGS
12.1 List of Night Vision Disturbances Pipeline Drugs Across the Top 7 Markets
12.1.1 Phentolamine mesylate ophthalmic solution - Ocuphire Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. NIGHT VISION DISTURBANCES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. NIGHT VISION DISTURBANCES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 NIGHT VISION DISTURBANCES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Night Vision Disturbances - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Night Vision Disturbances - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Night Vision Disturbances - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Night Vision Disturbances - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Night Vision Disturbances - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Night Vision Disturbances - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Night Vision Disturbances - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Night Vision Disturbances - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Night Vision Disturbances - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Night Vision Disturbances - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Night Vision Disturbances - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Night Vision Disturbances - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Night Vision Disturbances - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Night Vision Disturbances - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Night Vision Disturbances - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Night Vision Disturbances - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Night Vision Disturbances - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Night Vision Disturbances - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Night Vision Disturbances - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Night Vision Disturbances - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Night Vision Disturbances - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Night Vision Disturbances - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Night Vision Disturbances - Access and Reimbursement Overview
16 NIGHT VISION DISTURBANCES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 NIGHT VISION DISTURBANCES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 NIGHT VISION DISTURBANCES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
